Skip to results

Keyword or reference number

Keyword or reference number

Consultation end date

Consultation end date

Type

Guidance programme

Guidance programme

HealthTech approach

HealthTech approach

Showing 1 to 24 of 24

Guidance and quality standards in consultation
TitleConsultationTypeConsultation end date
Topical tapinarof for treating atopic dermatitis in people 2 years and over ID6713Consultation on suggested remit, draft scope and provisional stakeholder list of consultees and commentatorsTechnology appraisal guidance
Topical tapinarof for treating mild to severe plaque psoriasis ID6712Consultation on suggested remit, draft scope and provisional stakeholder list of consultees and commentatorsTechnology appraisal guidance
Software with artificial intelligence (AI)-derived algorithms to help interpret electroencephalograms (EEGs) for suspected epilepsy: early-use assessmentDraft guidanceHealthTech guidance
Resmetirom for treating non-alcoholic steatohepatitis and liver fibrosis [ID6529]Draft guidanceTechnology appraisal guidance
Teclistamab for treating relapsed or refractory multiple myeloma after 1 or more treatments ID6628Consultation on suggested remit, draft scope and provisional stakeholder list of consultees and commentatorsTechnology appraisal guidance
Mezigdomide with dexamethasone and carfilzomib for treating relapsed or refractory multiple myeloma after at least 1 line of treatment ID6513Consultation on suggested remit, draft scope and provisional stakeholder list of consultees and commentatorsTechnology appraisal guidance
Xanomeline tartrate–trospium chloride for treating schizophrenia ID6716Consultation on suggested remit, draft scope and provisional stakeholder list of consultees and commentatorsTechnology appraisal guidance
Semaglutide 7.2 mg dose for managing obesity ID6699Consultation on suggested remit, draft scope and provisional stakeholder list of consultees and commentatorsTechnology appraisal guidance
Vamikibart for treating uveitic macular oedema ID6671Consultation on suggested remit, draft scope and provisional stakeholder list of consultees and commentatorsTechnology appraisal guidance
NICE Funding Variation Request ConsultationMethods / process manual consultationNICE process and methods
Niraparib with abiraterone acetate and prednisone for treating hormone-sensitive metastatic prostate cancer [ID6595]Consultation on suggested remit, draft scope and provisional stakeholder list of consultees and commentatorsTechnology appraisal guidance
Zongertinib for treating HER2-mutated unresectable or metastatic non-small-cell lung cancer ID6573Consultation on suggested remit, draft scope and provisional stakeholder list of consultees and commentatorsTechnology appraisal guidance
Avapritinib for treating inadequately controlled moderate to severe indolent systemic mastocytosis [ID6578]Draft guidanceTechnology appraisal guidance
Inavolisib with palbociclib and fulvestrant for treating recurrent hormone receptor-positive HER2-negative PIK3CA-positive advanced breast cancer after adjuvant endocrine treatment [ID6425]Draft guidanceTechnology appraisal guidance
Tafasitamab with lenalidomide and rituximab for treating relapsed or refractory follicular lymphoma after 1 or more systemic treatments [ID6413]Draft guidanceTechnology appraisal guidance
Endouterine-ultrasound guided transcervical radiofrequency ablation for fibroidsDraft scope consultationHealthTech guidance
Atezolizumab with chemotherapy for adjuvant treatment of stage 3 colorectal cancer with high microsatellite instability or mismatch repair deficiency [ID6646]Consultation on suggested remit, draft scope and provisional stakeholder list of consultees and commentatorsTechnology appraisal guidance
Transvaginal radiofrequency ablation for symptomatic uterine fibroidsDraft scope consultationHealthTech guidance
Diabetes in pregnancy: management from preconception to the postnatal period - Managing type 1 diabetes (T1D) using hybrid closed loops (update)Draft guidance consultationNICE guideline
Digital technologies for the early detection and initial diagnosis of adult hearing loss (provisional title)ScopingHealthTech guidance
Zanidatamab with chemotherapy with or without tislelizumab for untreated HER2-positive unresectable advanced gastro-oesophageal adenocarcinoma ID6672Consultation on suggested remit, draft scope and provisional stakeholder list of consultees and commentatorsTechnology appraisal guidance
Ex-situ machine perfusion devices to preserve deceased donor livers for transplantationDraft guidanceHealth technology evaluation
Neurostimulation of lumbar muscles for refractory non-specific chronic low back painDraft scope consultationHealthTech guidance
Atogepant for treating migraine [ID6615]Final draft guidanceTechnology appraisal guidance

Results per page

  1. 10
  2. 25
  3. 50
  4. All